PF-06424439

CAT:
804-HY-108341-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
PF-06424439 - image 1

PF-06424439

  • UNSPSC Description:

    PF-06424439 is an oral, potent and selective imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC50 of 14 nM[1]. PF-06424439 is slowly reversible, time-dependent inhibitor, which inhibits DGAT2 in a noncompetitive mode with respect to the acyl-CoA substrate[2].
  • Target Antigen:

    Acyltransferase
  • Type:

    Reference compound
  • Related Pathways:

    Metabolic Enzyme/Protease
  • Applications:

    Metabolism-sugar/lipid metabolism
  • Field of Research:

    Metabolic Disease
  • Assay Protocol:

    https://www.medchemexpress.com/pf-06424439.html
  • Purity:

    99.89
  • Solubility:

    DMSO : 100 mg/mL (ultrasonic;warming;heat to 60°C)
  • Smiles:

    O=C([C@H]1CN(C2=CC=C3C(NC(C4(N5N=CC(Cl)=C5)CC4)=N3)=N2)CCC1)N6CCCC6
  • Molecular Weight:

    439.94
  • References & Citations:

    [1]Futatsugi K, et al. Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2). J Med Chem. 2015 Sep 24;58(18):7173-85.|[2]Pabst B, et al. Mechanistic Characterization of Long Residence Time Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2). Biochemistry. 2018 Dec 26;57(51):6997-7010.bioRxiv. 2023 Jul 3.|Dev Comp Immunol. 2021 Jul 3;104197.|Int J Biol Macromol. 2024 Nov 3:137235.|Nat Commun. 2024 Sep 27;15(1):8273.|Research Square Preprint. 2024 Feb 12.|Theranostics. 2024 Jun 1;14(9):3470-3485.|Int Immunopharmacol. 2024 Jun 24:138:112518.|J Biol Chem. 2024 Mar 13:107168.|J Dairy Sci. 2022 Feb 15;S0022-0302(22)00089-3.|J Dairy Sci. 2024 Jun 6:S0022-0302(24)00897-X.|J Virol. 2021 Nov 10;JVI0147321.|Mol Metab. 2024 May 4:101953.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    -20°C, 3 years; 4°C, 2 years (Powder)
  • Clinical Information:

    No Development Reported
  • CAS Number:

    1469284-78-3